Immunocore FY2023 KIMMTRAK sales $238.7M; launches PRAME Phase 3 with BMS

Immunocore Holdings plc

2023-FY EPS reported -$1.13 revenue$249,428,000

Q4 2023 KIMMTRAK net sales $67.6M; full year $238.7M (+12% YoY). US $169.8M, Europe $67.6M.
Net loss FY2023 $55.3M ($1.13 loss per share) vs $52.5M in 2022. R&D $163.5M, SG&A $144.5M.
Cash $442.6M at Dec 31; raised $389.3M net in Feb 2024 via 2.5% convertible notes due 2030.
Entered collaboration with BMS for Phase 3 PRISM-MEL301 trial of IMC-F106C + nivolumab in 1L advanced melanoma; first patient Q1 2024.
Multiple PRAME data readouts in 2024: cutaneous melanoma (Q2), ovarian (Q3), NSCLC (Q4). KIMMTRAK now in 12 launched countries.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.